- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04889404
LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)
LYNPARZA Tablets 100 mg, 150mg General Drug Use-results Study in Patients on Maintenance Treatment After Platinum-based Chemotherapy for BRCA Mutated Curatively Unresectable Pancreas Cancer
Study Overview
Status
Conditions
Detailed Description
To collect and characterise the incidence of adverse events related to the safety specifications*1 of the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated pancreatic cancer under the actual post-marketing use of LYNPAZA.
This investigation will be conducted for application for re-examination specified in Article 14-4 of the Pharmaceutical Affairs Law.
*1: Bone marrow depression, interstitial lung disease, new primary malignancies, and embryofoetal toxicity
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Study Locations
-
-
-
Aichi, Japan
- Recruiting
- Research Site
-
Chiba, Japan
- Recruiting
- Research Site
-
Fukuoka, Japan
- Recruiting
- Research Site
-
Gunma, Japan
- Recruiting
- Research Site
-
Hiroshima, Japan
- Recruiting
- Research Site
-
Hokkaido, Japan
- Recruiting
- Research Site
-
Hyogo, Japan
- Recruiting
- Research Site
-
Hyogo, Japan
- Completed
- Research Site
-
Ibaraki, Japan
- Recruiting
- Research Site
-
Kagawa, Japan
- Recruiting
- Research Site
-
Kanagawa, Japan
- Recruiting
- Research Site
-
Kyoto, Japan
- Recruiting
- Research Site
-
Kyoto, Japan
- Completed
- Research Site
-
Nagano, Japan
- Recruiting
- Research Site
-
Nagano, Japan
- Completed
- Research Site
-
Nagasaki, Japan
- Recruiting
- Research Site
-
Nara, Japan
- Recruiting
- Research Site
-
Okayama, Japan
- Recruiting
- Research Site
-
Osaka, Japan
- Recruiting
- Research Site
-
Shizuoka, Japan
- Recruiting
- Research Site
-
Tokyo, Japan
- Recruiting
- Research Site
-
Tottori, Japan
- Recruiting
- Research Site
-
Toyama, Japan
- Recruiting
- Research Site
-
Yamagata, Japan
- Recruiting
- Research Site
-
-
Lyn010001
-
Osaka, Lyn010001, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010003
-
Kanagawa, Lyn010003, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010004
-
Okayama, Lyn010004, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010005
-
Akita, Lyn010005, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010006
-
Niigata, Lyn010006, Japan, D081FC00004
- Completed
- Research Site
-
-
Lyn010007
-
Shizuoka, Lyn010007, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010008
-
Niigata, Lyn010008, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010009
-
Tokyo, Lyn010009, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010010
-
Saitama, Lyn010010, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010011
-
Aichi, Lyn010011, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010012
-
Osaka, Lyn010012, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010013
-
Tokyo, Lyn010013, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010014
-
Nara, Lyn010014, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010015
-
Wakayama, Lyn010015, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010016
-
Miyagi, Lyn010016, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010017
-
Tokyo, Lyn010017, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010018
-
Osaka, Lyn010018, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010019
-
Gunma, Lyn010019, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010020
-
Hiroshima, Lyn010020, Japan
- Recruiting
- Research Site
-
-
Lyn010021
-
Tochigi, Lyn010021, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010022
-
Iwate, Lyn010022, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010025
-
Osaka, Lyn010025, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010026
-
Shizuoka, Lyn010026, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010027
-
Nagasaki, Lyn010027, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010028
-
Kumamoto, Lyn010028, Japan, D081FC00004
- Completed
- Research Site
-
-
Lyn010029
-
Saitama, Lyn010029, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010031
-
Nagano, Lyn010031, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010032
-
Hyogo, Lyn010032, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010033
-
Shimane, Lyn010033, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010034
-
Hyogo, Lyn010034, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010035
-
Shizuoka, Lyn010035, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010036
-
Hyogo, Lyn010036, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010038
-
Okayama, Lyn010038, Japan, D081FC00004
- Recruiting
- Research Site
-
-
Lyn010041
-
Fukuoka, Lyn010041, Japan
- Recruiting
- Research Site
-
-
Lyn010042
-
Hokkaido, Lyn010042, Japan
- Recruiting
- Research Site
-
-
Lyn010044
-
Ehime, Lyn010044, Japan
- Recruiting
- Research Site
-
-
Lyn010045
-
Osaka, Lyn010045, Japan
- Recruiting
- Research Site
-
-
Lyn010047
-
Shizuoka, Lyn010047, Japan
- Recruiting
- Research Site
-
-
Lyn010050
-
Tokyo, Lyn010050, Japan
- Recruiting
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients who receive LYNPARZA for the first time for the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated curatively unresectable pancreas cancer after the approval date of partial change application for the additional indication (25/Dec./2020).
Exclusion Criteria:
- Patients who have no treatment history with LYNPARZA
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events related to the safety specifications
Time Frame: from baseline to 1year
|
Safety specifications:Bone marrow depression, interstitial lung disease, new primary malignancies, and embryofoetal toxicity
|
from baseline to 1year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Toshimitsu Tokimoto, AstraZeneca KK
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D081FC00004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
IPD Sharing Access Criteria
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Neoplasms
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
The First Affiliated Hospital with Nanjing Medical...RecruitingLocally Advanced Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer | Pancreatic NeoplasmChina
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
National Cancer Institute (NCI)CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
University of OxfordNational Institute for Health Research, United Kingdom; ImunonWithdrawnPancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV | Pancreatic Cancer Non-resectableUnited Kingdom
-
Mayo ClinicNational Cancer Institute (NCI)CompletedAdvanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic Carcinoma | Pancreatic Neoplasm | Locally Advanced Pancreatic CarcinomaUnited States
-
Maria LiljeforsKarolinska University Hospital; Karolinska Institutet; CelgeneCompletedPancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma MetastaticSweden